Access
To read this story in full you will need to login or make a payment (see right).
news feature
Nature 410, 622-625 (5 April 2001) | doi:10.1038/35070659
Open Innovation Challenges
-
Single-cell Analysis Platform
This Challenge is looking for novel approaches to analyzing changes at a single-cell level. This is...
-
Novel Approaches to Protecting Maize from Insect Damage
The Seeker is looking for novel approaches to protecting maize from insect damage. This Challenge re...
- More Challenges
- Powered by:
nature jobs
Neuroscience Faculty Positions
- University of Tennessee Health Science Center
- Memphis, Tennessee, USA
Clinical Trial Analyst
- Indegene Lifesystems Pvt. Ltd
- Bengaluru 560 071 India
Can they rebuild us?
Peter Aldhous1
Abstract
The idea of therapeutic cloning, which offers the potential of growing replacement tissues perfectly matched to their recipients, is falling from favour. But there are alternatives, as Peter Aldhous found out.
Take two of the biological breakthroughs of the late 1990s and combine them to produce a medical miracle — that is the thinking behind therapeutic cloning. The achievements are the cloning technology that in February 1997 gave us Dolly the sheep1, and the successful creation the following year of cultures of human embryonic stem (ES) cells2.
To read this story in full you will need to login or make a payment (see right).
